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Abstract
Cell-free HIV-1 virions are poor stimulators of type I interferon (IFN) production. We examined here how HIV-infected cells
are recognized by plasmacytoid dendritic cells (pDCs) and by other cells. We show that infected lymphocytes are more
potent inducers of IFN than virions. There are target cell-type differences in the recognition of infected lymphocytes. In
primary pDCs and pDC-like cells, recognition occurs in large part through TLR7, as demonstrated by the use of inhibitors
and by TLR7 silencing. Donor cells expressing replication-defective viruses, carrying mutated reverse transcriptase, integrase
or nucleocapsid proteins induced IFN production by target cells as potently as wild-type virus. In contrast, Env-deleted or
fusion defective HIV-1 mutants were less efficient, suggesting that in addition to TLR7, cytoplasmic cellular sensors may also
mediate sensing of infected cells. Furthermore, in a model of TLR7-negative cells, we demonstrate that the IRF3 pathway,
through a process requiring access of incoming viral material to the cytoplasm, allows sensing of HIV-infected lymphocytes.
Therefore, detection of HIV-infected lymphocytes occurs through both endosomal and cytoplasmic pathways.
Characterization of the mechanisms of innate recognition of HIV-infected cells allows a better understanding of the
pathogenic and exacerbated immunologic events associated with HIV infection.
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Introduction
HIV-1 infection is characterized by acute and chronic activation
of the immune system [1,2,3]. Inappropriate innate and
inflammatory responses trigger a cascade of events that deregulate
T cell turnover, function and localization. B cells are polyclonally
activated, the function of NK cells is impaired, circulating
dendritic cells are decreased. This hyperactivation leads to a
dysfunction of HIV-specific cellular and humoral immunity, and
represents a driving force for CD4+ depletion, facilitation of viral
replication, and AIDS progression. In natural hosts of SIV (such as
African Green Monkeys and Sooty Mangabeys), the infection is
generally non-pathogenic, despite high steady-state levels of
plasma viral RNA. The most striking difference with pathogenic
SIV infection in macaques is a lack of chronic activation in natural
hosts [4]. Very early events, occurring within the first hours or
days of viral exposure, likely influence the outcome of infection
[5,6]. The innate immune response, assessed by measuring type I
interferons (IFN) and other cytokines, distinguishes non-patho-
genic and pathogenic SIV infections. In natural hosts, type I IFN
production is transient after viral inoculation [7,8], and this may
be related to low levels of Toll-Like Receptor (TLR) 7 and 9
signaling [6], or to an efficient down-regulation of acute type I IFN
response [9]. In macaques, where SIV infection is pathogenic, an
intense signaling occurs in the mucosae at the portal of viral entry,
involving chemokines and a local accumulation of plasmacytoid
dendritic cells (pDCs) producing type I IFN [5]. It is likely that
similar early events are occurring during HIV-1 transmission and
acute infection, which is often associated with a high production of
IFN and pro-inflammatory cytokines [1]. However, the interac-
tions between HIV-1, pDCs and other cells leading to cytokine
production remain only partly characterized.
pDCs are a main component of the innate antiviral immune
system. They are the major source of type I IFN and other
antiviral cytokines, and contribute to the induction of adaptive
immunity (reviewed in [10]). Viruses are detected by pDCs mainly
through recognition of viral nucleic acids. These cells express
TLR7 and 9 endosomal molecules, which recognize single
stranded RNA (ssRNA) and unmethylated CpG-rich double
stranded DNA (dsDNA), respectively. TLR7 and TLR9 stimulate
IFN genes through IRF7 and inflammatory cytokines genes
through NF-kB (reviewed in [11]). The number of circulating
pDCs inversely correlates with plasma viral loads in HIV-infected
individuals ([12] [13]). In culture experiments, pDCs produce IFN
and other cytokines, and undergo phenotypic activation upon
exposure to HIV-1 [14,15,16,17]. IFN production by pDCs
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Gag p24) [14,15,18]. The mechanisms of HIV recognition by
innate receptors in pDCs are not fully understood. Both viral
proteins and nucleic acids represent potential targets of recogni-
tion. Detection may occur after viral uptake, in an endosomal
compartment, and/or after viral fusion, in the cytoplasm of target
cells. Recombinant HIV Envelope glycoproteins (Env) induce type
I IFN by PBMCs and pDCs, but also inhibit TLR9 activity
[19,20,21]. In pDCs, HIV capture and endosomal degradation
lead to viral RNA exposure and likely to TLR7 detection [15,18].
The role of TLR7 was deduced from experiments using inhibitors
of vesicular acidification and oligonucleotides targeting this
receptor, but a direct demonstration of TLR7 involvement is still
lacking. The ability of virion-associated Env to bind CD4
enhances IFN production by pDCs [22], but it is not clear
whether binding itself, or subsequent Env-mediated fusion events
mediate this phenomenon. After fusion, the viral RNA gains access
to the cytoplasm, where reverse transcription occurs. This could
lead to detection of nucleic acids by cytosolic sensors.
Besides pDCs, in most other cell types, viral nucleic acids may
be recognized by various cytosolic pattern recognition receptors,
including RLRs (RIG-I like Receptors). RLRs include DExD/H
box-containing RNA helicase Retinoic acid Inducible Gene I
(RIG-I) and Melanoma Differentiation Antigen 5 (MDA5). While
RIG-I senses 59-triphosphate RNA and short dsRNA (,1000 bp),
MDA5 senses long dsRNA [23,24,25,26,27]. Some DNA viruses
are also sensed by RIG-I, after transcription of viral DNA by RNA
pol III [28][29]. RIG-I and MDA5 stimulate IRF3 and NF-kB
through the adaptor MAVS (also termed Cardif, Visa or IPS1), to
produce IFN and inflammatory cytokines (reviewed in [11]). HIV
recognition by non-pDCs is not fully understood. Whatever the
cell type used, detection of cell-free HIV is generally considered
sub-optimal. In macrophages and lymphocytes, TREX1, a host
DNAse degrades HIV DNA generated during HIV infection,
providing a mechanism for the virus to avoid detection by nucleic
acid sensors [30]. However, CD4+ T cells from lymphoid tissues
may sense incomplete viral reverse transcripts, and these abortive
viral DNA products activate a host defense program eliciting
proapoptotic and proinflammatory responses [31]. Monocytic-
derived DCs are poorly sensitive to HIV infection, and produce
low levels of IFN when encountering HIV [14]. When this
resistance to productive infection is artificially circumvented, HIV-
1 induces DC maturation and type I IFN production [32]. This
cryptic process relies on the interaction of newly synthesized viral
capsid with cellular cyclophilin [32].
Most of the studies regarding the sensing of HIV-1 have been
performed with cell-free virions. However, PBMCs and pDCs
efficiently sense HIV-infected CD4+ T lymphocytes [33,34], but
the cellular and molecular mechanisms involved are not
characterized. Here, we examined how HIV-infected cells are
recognized by pDCs, and by other cells. We show that infected
lymphocytes are more potent inducers of IFN than free viral
particles. We describe cell-type differences in the recognition of
infected cells. In primary pDCs and pDC-like cells, recognition
occurs mainly through TLR7. We provide evidence for additional
pathways of sensing of infected cells. In a model of TLR7-negative
non-immune cell, we show that the IRF3 pathway allows sensing
of HIV-infected cells. Moreover, we show that cells expressing
defective viruses are also recognized by PBMCs and may thus
represent an underestimated source of hyperactivation of the
immune system.
Results
Primary hematopoı ¨etic cells efficiently sense HIV-infected
cells
We first examined whether PBMCs and pDCs produce IFN
when they encounter HIV-1. We compared the efficiency of
recognition of infected cells and cell-free virions. We used as donor
cells the MT4C5 lymphoid line (a derivative of MT4 cells
expressing CCR5), which can be infected by CXCR4-tropic (X4)
or CCR5-tropic (R5) HIV strains. Targets were fresh PBMCs
isolated from healthy donors. Typically, pDCs, identified as
BDCA4/BDCA2 double positive cells, represented 0.2 to 1 % of
whole PBMCs (Fig. S1a). We also used as targets PBMCs depleted
of pDCs (after removal of .80% of pDCs), or purified pDCs
(corresponding to .85% of purity based on BDCA2/BDCA4+
double labeling) (Fig. S1a). Influenza virus (FLUAV, 40 HAU/
mL), a well-characterized IFN inducer [35] was used as a positive
control (Fig. 1b).
MT4C5 cells were infected with HIV-1 (X4 strain NL4-3). After
two days of infection, when about 50% of the population was
Gag+, MT4C5 cells were cocultivated with target cells. After 12 to
22 hours of coculture, IFN was measured in supernatants using a
biological activity assay, and levels of HIV capture by targets were
assessed by flow cytometry (the experimental protocol is outlined
Fig. 1a). PBMCs were in parallel exposed to cell-free HIV (at
500 ng/mL Gag p24, a viral concentration corresponding to that
reached in supernatants of infected MT4C5 cells during the
coculture) (Fig. 1b). Strikingly, HIV-infected MT4C5 cells induced
10-100 times more IFN (mean of 600 U/ml) than cell-free HIV
virions. Non-infected donor cells did not activate PBMCs (not
shown). The supernatant of HIV-infected MT4C5 cells was not
more active than purified viral particles (not shown).
When cocultivated with HIV-1 infected cells, PBMCs depleted
of pDCs produced 10 times less IFN compared to total PBMCs
(Fig. 1b). Conversely, purified pDCs produced huge amounts of
IFN (up to 2,500 U/ml) (Fig. 1b). Thus, among circulating
hematopoı ¨etic cells, the early production of IFN induced by HIV-
1 infected cells mainly originates from pDCs. To confirm this
activation, we examined the induction of MxA, an IFN-stimulated
Author Summary
AIDS is characterized by a hyperactivation of the immune
system. Innate and inflammatory responses, associated
with an exacerbated production of cytokines like type I
interferons (IFN) and of chemokines, deregulate the
normal functioning of T lymphocytes and other cells. The
events that trigger this inappropriate activation remain
poorly understood. Plasmacytoid dendritic cells (pDCs)
normally produce IFN when they encounter viruses. Here
we examined how HIV-infected cells are recognized by
pDCs, as well as by other immune and non-immune cells.
We show that viruses transmitted via cell-to-cell contacts
are more potent inducers of IFN than cell-free viral
particles. In pDCs, recognition occurs in large part through
TLR7, a cellular receptor detecting viral genetic materials
after capture in intracellular vesicles. Donor cells express-
ing replication-defective viruses are also able to trigger IFN
production by target cells. We further show that in TLR7-
negative, non-hematopoietic cells an additional cytoplas-
mic pathway allows sensing of HIV-infected lymphocytes.
Therefore, detection of HIV-infected lymphocytes occurs at
different intracellular localizations, and does not require
ongoing viral replication. Characterization of the mecha-
nisms of innate HIV-1 recognition allows a better
understanding of the pathology of HIV infection, and has
consequences for the design of vaccine strategies.
Sensing of HIV-Infected Cells
PLoS Pathogens | www.plospathogens.org 2 February 2011 | Volume 7 | Issue 2 | e1001284Figure 1. Sensing of HIV-infected lymphocytes by hematopoı ¨etic cells. a. Schematic representation of the experimental system. HIV-
1 infected T cells are mixed with PBMCs, and levels of IFN released in supernatants are measured 12-24h later. b. IFN release in cocultures of HIV-
infected T cells with PBMCs. MT4C5 lymphoblastoid T cells (left panel) or primary CD4+ T lymphocytes (right panel) were used as donors. Whole
PBMCs, PBMCs depleted of pDCs (PBMCs-pDCs), and purified pDCs where used as target cells. Targets were either left non stimulated (NS),
cocultivated with non-infected (NI) or HIV-infected (NL4-3 strain) MT4C5 cells (MT4C5-HIV), exposed to cell-free HIV virions (free HIV) or Influenza virus
(FLUAV). IFN production in supernatants was measured in a bioassay, after 12 h of culture. Donor to target cell ratio were 1:2 for PBMCs and PBMCs-
pDCs, and 2:1 for pDCs. c. Dose response analysis of IFN release. Whole PBMCs were incubated with MT4C5 cells displaying increasing % of
infected (Gag+) cells. IFN production was measured after 24 h of coculture (orange histrograms). The levels of living MT4C5 cells at the beginning of
the coculture, determined by flow cytometry (forward and side scatters gating), are shown in blue. d. Sensing of cells infected with various HIV
isolates by PBMCs. MT4C5, infected with NL4-3 (NL), NLAD8 (AD8) and with two primary isolates (BON and 132W) were cocultivated with PBMCs
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expressed by sorted pDCs cocultivated with HIV-infected
MT4C5, or exposed to a high dose of cell-free HIV particles
(1200 ng/ml p24), and not at a lower inoculum (600 ng/ml) (Fig.
S1b). Therefore, HIV-infected cells promote IFN release and MxA
expression by pDCs.
Other types of HIV-infected lymphocytes, like Jurkat cells (not
shown) and primary CD4+ T cells (Fig. 1b), also promoted IFN
production by PBMCs, demonstrating that this phenomenon is
not an artifact due to the use of MT4C5 cells as donors. We also
ruled out the possibility that the combined stimulus of HIV and
mismatched HLA in heterologous cocultures of primary cells may
induce a strong activation of IFN production. Direct infection of
PHA-activated PBMCs with cell-free HIV lead to viral replication,
with a peak of infected cells at day 3 post-infection (Fig. S2). IFN
was also produced in supernatants, with a peak correlating with
viral production. Therefore, the presence of HIV virions and
infected cells triggers IFN release by PBMCs even in the absence
of heterologous cells.
MT4C5 cells were then infected with various doses of HIV-1.
After 2 days, the percentage of Gag+ cells varied from 10 to 80%,
and cell viability inversely correlated with the extent of infection
(Fig. 1c). After coculture with PBMCs, IFN production increased
with the percentage of HIV-infected donor cells, with a peak at
50% of Gag+ donor cells. When 80% of donor cells were infected,
viability of donor cells was low, accounting for the reduced IFN
levels released by PBMCs (Fig. 1c). We then induced apoptosis of
MT4C5 cells by treatment with Etoposide or Camptotecin (up to
40% of apoptotic cells, not shown). Apoptotic MT4C5 cells did
not elicit IFN release by primary PBMCs (not shown). This
suggests that the apoptotic events associated with HIV infection
are not responsible for the activation of pDCs. The experiments
described above were performed at a ratio of 1 donor for 2 target
PBMCs (1:2). At a lower ratio (1:5 to 1:10), levels of IFN
diminished progressively, likely reflecting the decreased capture of
viral materials by target cells (not shown).
We also examined if infected MT4C5 cells may have produced
very low levels of type I IFN that could trigger a secondary
response by pDCs. However, we could not detect IFN production
by HIV-infected MT4C5 cells, using three sensitive assays:
measurement of type I IFN in supernatants with the Luminex
technology, with a biological activity assay, and by quantifying
type I IFN mRNA in infected cells by qPCR (not shown).
Similarly, HIV-infected MT4C5 cells did not induce type I IFN
when mixed with uninfected MT4C5 cells (not shown). This lack
of type I IFN production by HIV-infected MT4C5 cells, as well as
by cocultures of infected and non-infected MT4C5 cells will
require further investigation, and is in line with a known disruption
of innate antiviral signaling and immune defenses within infected
cells [37]. Moreover, the addition of uninfected MT4 cells did not
enhance the detection of cell-free HIV by PBMCs, when assessed
at 12 h of incubation (not shown). At later time points, MT4C5
cells became infected and activated PBMCs (not shown).
We next tested the ability of various HIV-1 strains to induce
IFN production. MT4C5 cells, infected with three R5 isolates (the
reference strain NLAD8 and two primary viruses BON and 132W
[38]) induced similar levels of IFN in PBMC targets (Fig. 1d),
indicating that this phenomenon is not restricted to laboratory-
adapted viruses.
It is noteworthy that there were some donor-to-donor variations
in the levels of IFN response to HIV-infected cells. All of the 16
different donors tested produced type I IFN after a 12 h-coculture
with HIV-infected MT4C5 cells, with a range of 6006400 U/ml.
Together, the results indicate that induction of IFN in PBMCs
correlates with the level of infection but is also dependent on the
viability of donor cells. A high rate of cellular mortality does not
enhance IFN production by PBMCs. Various laboratory-adapted
and primary HIV isolates induce IFN.
Recognition of HIV-infected cells is enhanced by
functional viral envelope glycoproteins
In pDCs, the main cellular receptor mediating HIV binding is
the CD4 molecule. These cells, unlike myeloid DCs, express
neither DC-SIGN nor other lectins binding Envelope glycopro-
teins (Env) with high affinity [39]. Accordingly, antibodies against
CD4 or Env inhibit activation of pDCs by HIV virions [15,22].
We extended this observation, and asked whether Env is required
for the recognition of HIV-infected cells by PBMCs. We used as
donors MT4C5 cells producing an Env-deleted (DEnv) or a fusion-
defective HIV (F522Y mutant) [40]. F522Y carries a point
mutation in Env, which abrogate fusion but retains CD4 binding
ability. Since these viruses are not infectious, MT4C5 cells were
infected with DEnv or F522Y particles pseudotyped with a VSV-G
envelope, to ensure viral entry. DEnv-infected MT4C5 barely
elicited IFN release by PBMCs, and there was a two-fold decrease
in the potency of F522Y-infected cells to activate PBMCs, when
compared to WT HIV (Fig. 1e). The level of viral binding or
capture by PBMCs was assessed by measuring the % of Gag+
target cells by flow cytometry, after 12 hours of coculture (Fig. 1e).
WT and F522Y HIV were similarly uptaken by target PBMCs,
whereas DEnv, as expected, was less captured. Therefore, the
fusogenic activity of Env increases recognition of infected cells by
PBMCs. This suggests that recognition takes place mainly within
endosomes, but also once the virus has entered the cytoplasm of
target cells.
Pathways of recognition of HIV-infected cells by PBMCs
To determine the mechanisms by which PBMCs sense HIV-
infected lymphocytes, we first evaluated the effect of Bafilomycin
A1, an inhibitor of vesicular acidification. As controls we utilized
FLUAV and CpG, stimuli for TLR7 and TLR9, respectively [35]
[41]. Bafilomycin A1 (125 nM, a concentration that did not
detectably affected cell viability at 24 h, not shown) inhibited HIV
recognition (Fig. 2a), consistently with the requirement for an
acidic endosome and viral degradation in order to achieve TLR
signaling [15,42,43]. Of note, Bafilomycin A1 at 25 nM also
inhibited HIV recognition (not shown). FLUAV and CpG
stimulation were strongly inhibited by Bafilomycin A1, as
expected. We also tested the effect of A151, an oligonucleotide
described as a TLR antagonist, (inhibiting TLR7 and, to a lower
extent, TLR9) [15,43]. A151 (5 mg/mL) inhibited IFN production
by PBMCs cocultivated with HIV-infected MT4C5 cells (Fig. 2a).
At 5 mg/ml, A151 inihibited FLUAV, but not CpG stimulation of
PBMCs. At a higher concentration (20 mg/ml), A151 partly
and IFN was measured 24 h later. With all isolates, about 25% of infected MT4C5 cells expressed Gag before coculture. e. Role of HIV envelope
glycoproteins. MT4C5, infected with wild-type (HIV), Env-deleted (DEnv), or a non-fusogenic Env mutant (HIVF522Y), and with similar levels of Gag+
cells, were cocultivated with PBMCs and IFN was measured 12 h later (left panel). IFN levels are expressed as the % of the signal obtained with FLUAV.
MT4C5 viability was similar with WT, DEnv, and F522Y HIV at the beginning of the coculture. The efficiency of HIV capture by PBMCs was assessed by
measuring the % of Gag+ PBMCs by flow cytometry (right panel). Mean+sd of 3-5 independent experiments is shown, * p,0.05 (Kruskal-Wallis).
doi:10.1371/journal.ppat.1001284.g001
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PLoS Pathogens | www.plospathogens.org 4 February 2011 | Volume 7 | Issue 2 | e1001284Figure 2. Pathways of recognition of HIV-infected cells by hematopoı ¨etic cells. a. Effect of drugs targeting endosomal TLR signaling
or HIV reverse transcription in PBMCs. PBMCs were cocultivated with HIV-infected MT4C5 cells, exposed to FLUAV, or to CpG (a TLR9 agonist)
during 12 h, in the absence or presence of the indicated drugs. NVP (25 mM) is a reverse transcriptase inhibitor. Bafilomycin A1 (Bafilo, 125 nM) is an
inhibitor of vesicular acidification. A151 (5 mg/mL) is a TLR antagonist. Nevirapin (NVP 25 mM) is a reverse transcriptase inhibitor. IFN levels are
expressed as the % of the signal obtained without drugs. Mean+sd of 3 independent experiments is shown. *p,0.05 (Kruskal-Wallis). b-d. Viral
proteins required for the recognition of HIV-expressing cells by PBMCs. b. Schematic representation of the experimental system.
HeLa cells are transfected with various HIV mutants, cocultivated with PBMCs, and levels of IFN released in supernatants are measured 22 h later.
c. Defective viruses trigger IFN production by PBMCs. HeLa cells were transfected with the indicated proviral mutants. Supernatants were
harvested and analyzed for the presence of infectious virus, after normalization for Gag p24 levels. Env-deleted (DEnv), non-fusogenic Env (HIV
F522Y), reverse transcriptase (RT-), integrase (IN), protease (PR), Rnase H (RH), and nucleocapsid (NC44) mutants are not or poorly infectious (left
panel). Levels of IFN in supernatants, after coculture of tranfected HeLa cells with PBMCs. IFN levels are expressed as a percentage of the signal
obtained with WT HIV (right panel). d. Expression of Env alone does not trigger IFN production. HeLa-Env cells (stably expressing a functional
Env glycoprotein complex) were either not infected (NI) or infected with DEnv or WT viruses (pseudotyped with VSV), then processed and analyzed as
in c. c-d: Mean+sd of 2-3 independent experiments is shown. *p,0.05 (Kruskal-Wallis).
doi:10.1371/journal.ppat.1001284.g002
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compound may antagonize both TLR7 and TLR9. Altogether,
these results suggest that detection of HIV-infected cells by pDCs
and by PBMCs requires an acidic environment and is in large part
mediated by endosomal TLRs.
We thus asked whether viral reverse transcription plays a role in
this detection. Nevirapine, a reverse transcriptase (RT) inhibitor,
was pre-added on infected donor cells and maintained during the
coculture. With Nevirapine, the levels of Gag in targets cultivated
for 12 h with HIV-infected MT4 donor cells corresponded to
those observed with F522Y. At 36 h, Nevirapine decreased the
appearance of newly synthesized Gag proteins in PBMCs (not
shown). This suggested that Nevirapine did not prevent viral
capture by PBMCs but decreased at least partly subsequent
productive infection. Interestingly, Nevirapine did not inhibit IFN
production by PBMCs (Fig. 2a). Viral reverse transcription, and
hence neo-synthesis of viral DNA and further steps of the viral life
cycle, are thus probably not necessary to elicit IFN release.
Additional TLR-independent pathways involved in HIV
activation of PBMCs
While our data supports the engagement of TLRs on pDCs, the
decreased detection of envelope-deficient viruses suggested that
other sensors might also be implicated. That Nevirapine did not
inhibit IFN production suggests that reverse transcription and
productive infection are not required to activate targets. We used a
panel of viral mutants to document this observation further, and to
determine which step of the viral life cycle triggers immune
recognition of infected cells. We assessed the activity of viruses
carrying mutations in viral Reverse Transcriptase (RT), Integrase
(IN), RNAse H (RH), Protease (PR) enzymes. These defective
viruses are arrested at different steps of the viral cycle following
fusion and entry, leading to production of different types of viral
nucleic species in target cells. With the HIV RT- mutant, recipient
cells will only mainly ‘‘see’’ viral RNA genome. The HIV IN-
mutant synthesizes proviral DNA that will not integrate into the
host genome and will accumulate in the cytoplasm of target cells.
The RH- mutant is defective for the ribonuclease H activity, which
is necessary for viral RNA degradation during reverse transcrip-
tion, thus leading to a premature arrest of viral DNA synthesis
[44]. The PR- mutant is not infectious, since viral enzymes and
Gag and Gag-Pol precursors are not processed. We also evaluated
the efficacy of a virus mutated in the nucleocapsid (NC44 mutant)
[44]. This mutant loses about 90% infectivity, reverse transcription
prematurely occurs in producer cells and in viral particles, which
then contain abnormally high levels of proviral DNA.
Since these mutants do not infect lymphoid cells, we transfected
the corresponding proviral constructs in HeLa cells (Fig. 2b). We
also transfected WT, DEnv and F522Y mutants, to study the role
of viral access to the cytoplasm when donors are HeLa cells. Upon
transfection with this panel of viral mutants, HeLa cells displayed
similar levels of Gag+ cells (10-20%) and Gag p24 release (10–
50 ng/ml) in supernatants (not shown). As expected, these mutants
were not (DEnv and F522Y, RT-, IN-, RH-, PR-) or very poorly
(NC44) infectious when tested in a single cycle infectivity assay
(Fig. 2c). We then cocultivated HeLa cells with PBMCs for 22 h.
HeLa cells expressing WT HIV, and not control cells (transfected
with an irrelevant plasmid), induced IFN production by PBMCs
(up to 60 U/mL, not shown). This range of IFN is much lower
than that induced by HIV-infected lymphocytes (Fig. 1). This
reduction could be in part due to the lower production of HIV by
transfected HeLa cells, when compared to infected MT4C5 cells.
Interestingly, in this experimental system, DEnv- and F522Y-
expressing cells did not stimulate target cells. In contrast, all other
mutants elicited IFN production by PBMCs (Fig. 2c).
HeLa cells stably expressing a functional Env at their surface
(HeLa-Env cells) [45] did not elicit IFN production by PBMCs
(Fig. 2d). HeLa-Env cells also express Tat [45]. Therefore, the
presence of Tat in cocultures of Env+ cells and target PBMCs is
not sufficient to trigger type I IFN production. As expected,
infection of HeLa-Env cells with DEnv or WT HIV proviruses
restored activation (Fig. 2d). We also examined the effect of a
transient contact between donor and target cells. We harvested
target PBMCs after a 2 h-coculture with HIV-expressing HeLa
cells. This short contact was sufficient to induce type I IFN
production in target cells, albeit at lower levels than a continuous
coculture (not shown). Thus, activation of PBMCs in this system
does not require a sustained viral production by donor cells.
In sum, in this experimental setting characterized by a low level
of viral production by donor HeLa cells, the step of viral fusion
significantly enhances activation of target PBMCs. Expression of
Env alone is not sufficient to mediate sensing. Reverse transcrip-
tion, as well as later steps of the viral cycle do not enhance IFN
production, at least during the first 24 h of coculture. Moreover,
PBMCs efficiently sense cells producing defective viruses.
Sensing of HIV-infected cells by the Gen2.2 pDC-like cell
line
We sought to use the Gen2.2 pDC-like cell line to dissect the
pathways of recognition of HIV-infected cells. This cell line was
derived from a patient with pDC leukemia, and possesses
phenotypic and functional features of primary pDCs [46].
Gen2.2 cells express TLR7, TLR9 and other pDC markers. They
produce IFN when exposed to FLUAV or other TLR agonists,
although at lower levels than primary pDCs. Gen2.2 mature upon
incubation with very high concentration of HIV particles [16].
These cells represent a useful tool as they can be transduced with
lentiviral vectors encoding for shRNAs [47]. We first examined
whether Gen2.2 cells are sensitive to HIV replication. Like
primary pDCs [48], these cells express the HIV receptors CD4,
CXCR4 and CCR5 (Fig. 3a). Gen2.2 cells efficiently replicated
HIV, as assessed by measuring the appearance of Gag+ cells and
viral release by Gag p24 ELISA in supernatants at different time
points after infection (Fig. 3a). Viral release was particularly high,
reaching 1600 ng/ml Gag p24 at day 8 pi. IFN was also detected
in supernatants, but only at late time points (day 8–10 pi). IFN
release reached 15 U/ml, when about 30-40 % of Gen2.2 where
Gag+ (Fig. 3a). Gen2.2 cells thus replicate HIV-1 and produce
IFN upon infection.
Next, we examined how Gen2.2 cells reacted when encounter-
ing HIV-infected T cells. To this end, infected MT4C5 were
mixed with Gen2.2, and IFN levels were measured at 12 or 24 h of
coculture. IFN was barely detected at 12 h (not shown). At 24 h,
about 25 U/ml IFN were released in supernatants (Fig. 3c), which
is 10–30 fold less than in primary pDCs. FLUAV potently
activated Gen2.2 cells, whereas cell-free HIV particles (500 ng/ml
Gag p24) elicited no IFN release (Fig. 3c). We reported that a
gentle shaking of cocultures of infected cells and target cells
inhibits direct cell-to-cell viral spread [49]. Shaking cocultures of
HIV-infected MT4C5 cells and Gen 2.2 cells strongly decreased
IFN production, whereas induction by FLUAV was not affected
(Fig. 4a). Furthermore, IFN levels were below detection levels
when infected donors cells and target Gen2.2 recipients were
separated by a Transwell chamber (Fig. 4a). This strongly
suggested that a direct contact between HIV-infected lymphocytes
and Gen 2.2 cells is required to mediate recognition. Confirming
our observation made with primary pDCs, optimal recognition of
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PLoS Pathogens | www.plospathogens.org 7 February 2011 | Volume 7 | Issue 2 | e1001284infected cells required a functional Env, as evidenced by the low
levels of IFN (,1 U/ml) induced by DEnv- and F522Y-infected
MT4C5 cells. HIV capture by Gen2.2 cells was assessed by flow
cytometry after 12 h of coculture (Fig. 3c). WT and, to a slightly
lower extent, F522Y HIV were efficiently captured, whereas very
few Gen2.2 cells were Gag+ after contact with DEnv-expressing
lymphocytes. These differences in HIV capture by Gen2.2 cells
were already visible after 1 h of coculture, as evidenced by
immunofluorescence staining (Fig. 3d). WT and F522Y-infected
cells formed virological synapses or polysynapse-like structures
[50] with Gen2.2 cells, and patches of viral (Gag+) material were
readily transferred to targets. Of note, coculture of Gen2.2 with
HIV-1 infected primary CD4+ lymphocytes activated Gen2.2 as
efficiently as MT4C5 cells (Fig. 3c).
Therefore, although they produce less IFN, Gen2.2 cells behave
like primary pDCs and efficiently sense HIV-infected cells. As with
primary cells, Bafilomycin A1 (125 nM) inhibited HIV recognition
(Fig. 4a). We next assessed the involvement of TLR7 in the sensing
of HIV-infected cells. TLR7 expression was silenced by transduc-
tion of Gen2.2 cells with a lentiviral vector coding for an anti-
TLR7 shRNA. The vector also expressed a puromycin-resistance
gene, allowing selection of a population of transduced cells (termed
Gen2.2-shTLR7). Silencing decreased TLR7 mRNA levels by
80%, when compared to a control shRNA (Fig. 4b). Gen2.2-
shTLR7 cells produced about 10-fold less IFN than control cells,
when cocultivated with HIV-infected MT4C5 cells (Fig. 4b).
Response to FLUAV was impaired when TLR7 was downregu-
lated, whereas CpG stimulation was not affected. These
experiments directly demonstrate that TLR7 is a cellular receptor
mediating recognition of HIV-infected cells by pDCs.
Sensing of HIV-infected cells by TLR7-negative epithelial-
like cells
The experiments with fusion-defective viruses described above
implicated cytosolic receptors in HIV recognition. We asked
whether HIV-infected lymphocytes can be detected by additional,
TLR7 independent cellular pathways. To this end, we performed
cocultures with 293T cells as targets, as these latter do not express
TLR7, TLR9 and TLR3 [51] and are widely used to dissect
pathways of IFN signaling. We confirmed that 293T cells do not
express detectable levels of TLR7 mRNA by real-time PCR, and
that they are refractory to stimulation by the TLR7/8 agonist
Gardiquimod (not shown). Next, we evaluated whether HIV-1
infected lymphocytes could activate in 293T cells a luciferase
reporter that is under the control of the IFNb promoter (IFNb-
luc). This technique is widely used to assess the IFNb pathway in
293T cells [52,53,54,55], because the levels of IFN released in the
supernatants are below detection limits (not shown). Importantly,
there was no induction of luciferase over background levels, upon
coculture of HIV-infected MT4C5 cells with IFNb-luc transfected
293T cells (Fig. 5a). 293T cells lack HIV receptors CXCR4 and
CD4. We generated 293T cells expressing either CXCR4 (293T-
CXCR4) or both CD4 and CXCR4 (293T-4X4 cells). In contrast
to parental cells and to 293T-CXCR4 cells, 293T-4X4 cells
activated the IFNb promoter, when mixed with MT4C5 cells
infected with wild-type HIV (7 fold increase, when compared to
non-infected cells). Noteworthy, MT4C5 cells expressing either
DEnv or the non-fusogenic F522Y strain failed to elicit luciferase
activity (Fig. 5a). As a positive control, we used Sendai virus (SeV),
a parainfluenza virus that activates IFNb in 293T cells through the
RIG-I/IRF3 pathway [52,53,54]. Moreover, free HIV virions
(even at high concentrations) did not activate 293T-4X4 (not
shown). Altogether, these results indicated that viral fusion
activates the IFNb promoter in the absence of TLR7. Detection
of HIV-infected cells is more efficient than that of virions also in
this experimental system.
We characterized further the TLR7-independent pathways that
mediate recognition of HIV-infected cells. The binding of some
viral RNA to RIG-I and MDA5 helicases leads to conformational
changes that expose their CARD-like domains, induces binding to
MAVS, and down-stream signaling through IRF3 [53,56,57,58].
We thus silenced IRF3 expression in 293T-4X4 cells by siRNA
transfection. Western blot analysis confirmed that IRF3 was barely
detectable in silenced 293T-4X4 cells, whereas NFkB was not
affected (Fig. 5b). Interestingly, IRF3 was required for the
activation of the IFNb promoter in 293T-4X4 cells cocultivated
with HIV-infected cells (75% decrease in IRF3-silenced cells) or
exposed to SeV (90% decrease) (Fig. 5b). We then used the
ImageStream cytometer that combines flow cytometry with
intracellular localization of fluorescent proteins, to examine
nuclear translocation of IRF3. This technique allows a quantita-
tive assessment of the localization of transcription factors in a large
number of cells (a few thousands per sample) [59,60,61]. 293T-
4X4 cells were cocultivated with non-infected or HIV-infected
MT4C5 cells for 16 hours. MT4C5 cells were first stained with Far
Red dye, to distinguish them from 293T-4X4 cells. Fixed cells
were then stained with anti-IRF3 antibodies, and nuclei were
visualized with DAPI. Non-stimulated or SeV-exposed cells were
used as negative and positive controls, respectively. Images were
then captured in five chanels: darkfield, brightfield, Far Red,
DAPI, IRF3. Representative images of gated 293T-4X4 cells
displaying either a diffuse intracellular localization (non translo-
cated) or a colocalization with DAPI (translocated) are depicted
Fig. 5c. A quantitative analysis based on the similarity of IRF3 and
DAPI stainings revealed a 2-fold increase when 293T-4X4 were
incubated with HIV-infected cells (55% vs 28% for cocultures of
HIV-infected and non infected MT4C5 cells, respectively, Fig. 5d).
As expected, with SeV, there was a 3-4-fold increase in the
similarity score. Therefore, contact with HIV-infected cells
induces nuclear translocation of IRF3 in 293T-4X4 cells.
Figure 3. Recognition of HIV-infected cells by the Gen2.2 plasmacytoid-like cell line. a. Gen2.2 cells express HIV receptors and are
sensitive to HIV infection. Surface expression levels of CD4, CXCR4 and CCR5 are shown on the upper left panel. Gen2.2 cells were then exposed
to HIV particles, NL4-3 strain, at two doses (0.5 and 5 ng/0.1 ml Gag p24/10
6 cells). Viral replication was assessed by following the appearance of
Gag+ cells (upper right panel) and Gag p24 release in supernatants (lower left panel). IFN production was measured in the same supernatants (lower
right panels). Data are representative of 3 independent experiments. b. Schematic representation of the coculture system. HIV-1 infected T
cells are mixed with Gen2.2 cells and levels of IFN released in supernatants are measured 12–22 h later. c. Sensing of HIV-infected cells by
Gen2.2 and role of viral envelope glycoproteins. MT4C5, infected with wild-type (HIV), Env-deleted (DEnv), or a non-fusogenic Env mutant
(HIVF522Y), and with similar levels of Gag+ cells, were cocultivated with PBMCs and IFN was measured 22 h later (left panel). When stated, HIV-
infected primary CD4+ cells were used as donors, instead of MT4C5 cells. Cell-free HIV virions (500 ng/ml p24) do not stimulate Gen2.2 cells. The
efficiency of HIV capture by Gen2.2 was assessed by measuring the % of Gag+ cells by flow cytometry (right panel). Mean+sd of 10 independent
experiments is shown, *p,0.05 (Kruskal-Wallis). d. Visualization of HIV capture by Gen2.2 cells. Gen2.2 cells were labeled with CFSE (green)
and cocultured with MT4C5 infected with wild-type (HIV), DEnv and F522Y mutants. Cells were harvested after 1 h and stained for HIV Gag (red).
Representative fields are shown.
doi:10.1371/journal.ppat.1001284.g003
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endogenous TLR7 a pathway involving IRF3 triggers recognition
of HIV-infected cells.
Discussion
Our study delineates some features of HIV innate recognition.
Cell-free HIV particles are generally considered as poor inducers
of type I IFN [14,30,32]. We show here that HIV-infected cells are
much more potent stimulators of IFN than free viral particles,
confirming and extending previous findings [34]. Various cell
types may recognize HIV-infected lymphocytes. Among PBMCs,
pDCs are the main cells detecting HIV-infected cells, since their
removal strongly decreases IFN release. TLR7 senses HIV
components, but additional pathways are operative. Viral fusion
is an important step promoting HIV detection, whereas reverse
transcription and subsequent events of the viral life cycle are not
necessary to activate an immune response. Using a model of cells
lacking TLR7, we demonstrate that the IRF3 pathway participates
in HIV recognition. Therefore, the host innate response to HIV
involves the integration of multiple sensor pathways.
Why detection of HIV-infected cells is more efficient than that of
cell-free virions? A contact with infected cells promotes a massive
and rapid transfer of viral material to target cells [49], as visualized
hereinpDCsbyimmunofluorescenceandflowcytometry.Weshow
here, by shaking cocultures and by using transwell chambers, that a
direct contact between infected cells and recipients is required to
Figure 4. Role of cell contacts and of TLR7 on recognition of HIV-infected cells by Gen2.2 cells. a. Activation of Gen2.2 requires a direct
contact with HIV-infected cells. Shaking cocultures of Gen2.2 and HIV-1-infected MT4C5 (left panel), or separating infected MT4C5 cells and target
Gen2.2 in a transwell chamber (right panel) impairs IFN production, whereas recognition of FLUAV by Gen2.2 is not affected. Mean+sd of 3
independent experiments is shown b. Inhibition of IFN production by Bafilomycin A1. Gen2.2 cells were cocultivated with HIV-infected MT4C5
cells, exposed to FLUAV, or to CpG (a TLR9 agonist) during 24 h, in the absence or presence of Bafilomycin A1 (Bafilo 125 nM). IFN levels are
expressed as the % of the signal obtained without drugs. c. Role of TLR7. Gen2.2 cells were transduced with lentiviral vectors expressing shRNAs
against TLR7 (shTLR7) or an irrelevant target (shCTRL). Levels of TLR7 mRNA in transduced cells were measured by RT-PCR. Data are normalized to
GAPDH mRNA and expressed as relative levels of mRNA compared to shCTRL cells. Mean+sd of 3 independent experiments are shown (left panel).
IFN production in TLR7-silenced and control Gen2.2 cells, cocultivated with HIV-infected MT4C5 or stimulated with FLUAV or CpG for 40 h. IFN levels
are expressed as a percentage of the signal obtained with shCTRL Gen2.2 cells.
doi:10.1371/journal.ppat.1001284.g004
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PLoS Pathogens | www.plospathogens.org 10 February 2011 | Volume 7 | Issue 2 | e1001284trigger high levels of IFN release by these latter. Various modes of
cell-to-cell HIV transfer have been reported in culture, including
synapses, polysynapses, filopodial bridges and nanotube-like
structures [62]. HIV dissemination involves viral endocytosis in
target cells [63,64]. Whatever the mode of cell-to-cell transfer, the
viral influxis quantitatively more important than capture of cell-free
viral particles and may explain in part the potent induction of IFN
production. Furthermore, infected cells may produce additional
cellular or viral components that are not found in virions, which
may enhance the activation of target cells.
Detection of HIV-infected cells by pDCs and PBMCs requires
functional viral envelope glycoproteins. Envelope-deleted viruses
are not or poorly recognized, mainly because target cells capture
limited amounts of viral material in the absence of Env
glycoproteins. When produced in MT4C5 cells, the fusion-
defective envelope mutant (F522Y) is efficiently captured by
PBMCs, but its ability to stimulate pDCs is reduced. This raises
interesting mechanistic insights. F522Y HIV is normally up-taken
in the endosomal compartment but further access to the cytosol is
compromised [65]. Thus, there are multiple sites of recognition of
incoming material from HIV-infected cells. In endosomes, TLRs
may detect incoming HIV, as illustrated by the inhibitory effect of
Bafilmoycin A1 and of TLR antagonists. After fusion, additional
mechanisms of detection may enhance IFN production.
Several lines of evidence suggest that viral replication and
productive infection of PBMCs are not necessary to trigger a
response to infected cells. Nevirapine, a reverse transcriptase
inhibitor, does not inhibit IFN release by PBMCs. However, it is
possible that Nevirapine does not fully inhibit viral DNA synthesis
in coculture systems of viral cell-to-cell spread. As incomplete viral
DNA products represent a source of cytoplasmic nucleic acids that
activate an innate immune response [31], we examined the activity
of a series of viral mutants, arrested at different steps of the viral
cycle. We show that HeLa cells expressing defective viruses,
inactivated either in their reverse transcriptase, RNAse H,
integrase, protease or nucleocapsid, stimulate IFN release in
PBMC cocultures as efficiently as WT HIV. In this coculture
system, in which HeLa cells produce relatively low levels of virus,
viral fusion activity enhances recognition, as demonstrated with
DEnv and F522Y mutants that triggered low levels of IFN
production. Whether virus-cell or cell-cell fusion, or a combination
of both, cause PBMCs activation will require further investigation.
Cell-cell fusion is a feature of many viral infections, including HIV.
The resulting syncytia may represent a structure producing high
levels of IFN, as reported for Measles-induced giant cells [66].
Noteworthy, Env expression alone was not sufficient to activate
PBMCs. It will be worth assessing the stimulating effect of donor
cells producing particles devoid of HIV RNA.
The majority of HIV particles produced by an infected cell are
defective or lead to abortive infection [67] [31,68]. Defective
viruses are generated by reverse transcriptase errors, editing
activity of APOBEC proteins, and by various other mechanisms.
Our results suggest that cells producing non-replicating viruses, if
retaining fusion potential, may represent an underestimated source
of innate immune activators. Our results also confirm that abortive
infection may be sensed in target cells [31], thus triggering
apoptotic and inflammatory events.
To gain a mechanistic insight into how pDCs recognize HIV-
infected cells, we used the Gen2.2 pDC-like cell line as a model
[46]. We show that Gen2.2 cells, like primary pDCs, are sensitive
to HIV replication and release IFN upon coculture with HIV-
infected lymphocytes. We generated TLR7-negative Gen2.2 cells
by RNA silencing. These cells were impaired in IFN production
when cocultivated with HIV-infected lymphocytes, whereas CpG-
induced TLR9 signaling was normal. These results provide a
direct demonstration that TLR7 mediates recognition of HIV-
infected cells. In addition, Gen2.2 cells recognized fusion-defective
HIV significantly less potently than the wild-type virus, confirming
that sensing of HIV-infected cells may occur at different
intracellular locations in pDCs.
In this study, we also used 293T-derivatives as target cells.
These non-hematopoı ¨etic cells are not natural targets of HIV
infection, but represent a valuable model to study HIV recognition
in cells devoid of TLR7. In these targets, activation of the IFNb
promoter occurred upon coculture with HIV-infected lympho-
cytes, and not with free virions. Signaling required the expression
of fusogenic envelope in donor cells, and the presence of cognate
receptors (CD4 and CXCR4) in target cells. This strongly suggests
that viral or cellular components originating from donor cells need
to gain access to the cytoplasm of targets to activate the IFNb
promoter. We dissected further the signaling cascade leading to
this activation. Promoter activation required the IRF3 transcrip-
tion factor [55], as demonstrated by silencing this molecule. The
role of IRF3 was confirmed by directly visualizing with the
ImageStream apparatus its nuclear translocation, when target cells
encounter HIV-infected cells. Of note, SeV activated more
efficiently the IFNb promoter than HIV-infected cells. This
activation was particularly sensitive to IRF3 signaling (90%
decrease in IFNb promoter activity), and was associated with a
marked nuclear translocation of IRF3. Thus, the stimulating
effects of SeV and of HIV-infected cells on the IFN pathway are in
part similar, rely on IRF3, but are not totally overlapping. That
sensing of HIV-infected cells occurs via IRF3 signaling is in line
with two recent reports, demonstrating that this transcription
factor mediates recognition of HIV particles in different TLR7-
cell types, including MDDCs and macrophages [32] [30].
Figure 5. Sensing of HIV-infected lymphocytes by 293T-derived epithelial cells. a. Role of CD4 and CXCR4 in 293T cells. Activity of the
IFNb promoter in parental 293T cells, and in 293T cells expressing CXCR4 (293T CXCR4), or CD4 and CXCR4 (293T-4X4). These cells were transfected
with IFNb-luciferase reporter plasmid, and cocultivated for 16 h with MT4C5 cells expressing wild-type, DEnv, or F552Y HIV. The fold induction of
luciferase activity, compared to non-stimulated cells is shown. The paramyxovirus Sendai virus (SeV) was used as a positive control (right panel).
b. Role of IRF3. 293T-4X4 cells were transfected with an irrelevant (CTRL) or an anti IRF3 siRNA. 48 h later, cells were cocultivated with HIV-infected
MT4C5 cells and assayed for IFN-b promoter activity. Left panel: IRF3 and NFkB levels, assessed by western blot, in control (CTRL) and silenced 293T-
4X4 cells. Right panel: IFN-b promoter activity is expressed as a percentage of the signal obtained with control cells (CTRL). SeV, which signals
through IRF3, was used as a control. Mean+sd of 3 independent experiments is shown. *p,0.05 (Kruskal-Wallis). c–d. Automated quantification
of IRF3 nuclear translocation. 293T-4X4 cells were cocultivated with non-infected (NI) or HIV-infected Far-red dye stained MT4C5 cells, exposed to
SeV, or left non-stimulated (NS) for 16 h. Cells were then stained with anti-IRF3 Abs and nuclei were visualized with DAPI. Automated quantification of
IRF3 nuclear translocation on gated 293T-4X4 (Far-red dye negative) cells was performed using the ImageStream technology. c. Representative
images of Bright field, Dapi (blue) IRF3 (green), DAPI/IRF3 composite images, for cells with either a diffuse intracellular (non translocated, low
similiarity value) or a nuclear localization (translocated, high similarity value) are shown. d. 293T-4X4 cells with nuclear-localized IRF3 have higher
similarity values, because the aspect of IRF3 and DAPI staining is similar. The percentage of cells with similarity values above an arbitrary value of 1.5
(where most, if not all of the cells fall in the translocated category) is indicated on each histogram. Data are representative of 4 independent
experiments.
doi:10.1371/journal.ppat.1001284.g005
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the cytosolic molecules recognizing HIV-infected cells. The
cytosolic RLR (RIG-I-like receptors) helicases RIG-I and MDA5
may be involved in this phenomenon, since they directly recognize
multiple and distinct forms of intracellular dsRNA. For instance,
putative RIG-I ligands include 5-PPP-bearing RNAs, as well as
RNAs with complex secondary structures [69,70]. MDA5 binds to
long dsRNAs [27,71]. Addressing the role of RIG-I and MDA5 on
recognition of HIV-infected cells will require further investigation.
It will be also worth examining the implication of other cytosolic
sensors that have been recently identified as mediating or
modulating recognition of cell-free virions. This includes 39 repair
exonuclease 1 (TREX1) [72] and cyclophilin [32]. TREX1 acts as
a negative regulator of the IFN response to DNA species generated
during reverse transcription of endogenous retroelements [72].
TREX1 degrades HIV DNA and has been proposed to be used by
the virus to avoid triggering detection by DNA sensors [30].
Cyclophilin binding to newly synthesized HIV Gag proteins also
triggers an antiviral state in MDDCs [32]. It will be worth
determining the role of TRIM5 molecules that bind incoming
HIV capsids, regulate viral uncoating and thus exposure of HIV
nucleic acids in infected cells. Whatever the underlying mecha-
nism, our results demonstrate the existence of TLR7-independent
pathways involved in the innate host response against HIV-
infected cells.
What may be the relevance of this TLR7-independent signaling
pathway? MDDCs are poorly responsive to cell-free HIV: they do
not mature nor produce IFN when exposed to cell-free viral
particles [14]. However, circumventing the restriction of MDDC
to infection significantly enhances viral detection [32]. This innate
response is dependent on cyclophilin A and subsequent IRF3
activation [32]. It will be worth determining if HIV-infected cells
are sensed by MDDCs more potently than free virions, and if so,
examine the role of Gag- cyclophilin interactions in this process.
In sum, our results show that the innate immune system
efficiently senses HIV-infected lymphocytes. The potent recogni-
tion of HIV-infected cells may overcome the poor detection of cell-
free virions. Various cellular sensors are involved in this
recognition, which likely represents a driving force regulating the
pathology of infection, as well as the generation of an adaptative
immune response. How do the different sensor pathways interact
to coordinate the host response to viral infection remains an
outstanding question. Deciphering the basic mechanisms of HIV
recognition has obviously important implications for the develop-
ment of tailored vaccine strategies.
Materials and Methods
Cells, viruses and reagents
PBMCs were isolated from the blood of healthy donors by Ficoll
centrifugation. The blood was provided by the EFS (Etablissement
Franc ¸ais du Sang, the French Official Blood Bank). pDCs were
isolated by positive selection using anti-BDCA-4 magnetic beads
(Miltenyi Biotec). The negative fraction was collected and
constituted PBMCs depleted from pDCs. CD4+ T lymphocytes
were isolated from PBMCs by positive selection using magnetic
beads (Miltenyi Biotec). CD4+ T lymphocytes were activated by
PHA and grown with rhIL-2 for 3–5 days before infection.
MT4C5, Jurkat T cells, PBMCs, and primary lymphocytes were
grown in RPMI medium with 10% heat-inactivated fetal bovine
serum (FBS). Monocyte-derived DCs (MDDCs) were prepared
using GMCSF and IL-13-containing medium as described [73].
Isolation procedures yielded immature DC (CD1a+, MHC-I+,
MHC-II+, CD64-, CD83-, CD80-low, CD86-low cells). HeLa,
293T and derivatives were grown in DMEM supplemented with
10% FBS. 293T-4X4 and 293T CXCR4 were generated using
lentiviral transduction of 293T with lentiviruses coding for CD4
and/or CXCR4 molecules and magnetic sorting (Miltenyi Biotec).
P4C5 are HeLa-CD4+ CCR5+ cells expressing a HIV-LTR-
bGalactosidase reporter cassette. The pDC cell line Gen2.2 has
been described elsewere [46]. Gen2.2 cells were grown in RPMI
medium supplemented with 10% FBS, 1 mM sodium pyruvate
and non-essential amino acids. Hela-Env cells stably express
gp120/gp41 at the surface [45].
40 UHA/mL Influenza virus (FLUAV, A/PR/8/34, Charles
River Laboratories) was used to stimulate PBMCs, Gen2.2 and
293T-4X4. Sendai virus (SeV, Cantell strain, ATCC, VR-907
Parainfluenza 1) was kindly provided by Dominique Garcin [54]
and 4 UHA/mL were used to stimulate 293T-4X4. The
production and use of HIV strains, including NL4-3 and NLAD8,
NLDEnv and NLF522Y mutants, and primary isolates BON and
132W [38] have been described [42,65]. Viruses were either
produced by transfection of 293T cells or by infection of MT4C5
cells. NLF522Y provirus encodes a non-fusogenic gp120/g41 Env
complex [65]. Vesicular stomatitis virus type G (VSV-G)
pseudotyped viruses NLDEnv and NLF522Y were generated by
cotransfection of 293T cells with the corresponding proviruses and
a VSV-G expression plasmid.
Mutant proviruses
The Reverse Transcriptase defective virus (RT-) was designed
by replacing to D residues that form the catalytic site, DD185-
186AS [74]. The protease negative mutant includes a D25E
mutation in the enzyme. The Integrase mutants C130G (IN-) has
been described [75]. The RnaseH mutant E478Q (RH-) and
Nucleocapsid (NC44) have been described previously [74] [44].
Nevirapine (NVP, at 25 mM) is an inhibitor of HIV reverse
transcriptase provided by the NIH AIDS Research and Reference
Reagent Program. A151 (5 mg/mL), a TLR7 antagonist [43], was
synthesized by the Institut Pasteur Genopole. Bafilomycin A1
(125 nM) was purchased from Sigma-Aldrich. CpG-2216 (Invivo-
gen) was used at 5 mM.
siRNAs (anti-IRF3, sequence TCTGGATGAGTTACTGGG-
TAA ref SI03117359, and CTRL, sequence AATTCTCC-
GAACGTGTCACGT ref SI03650325) were from Qiagen, and
were transfected according to the manufacturer with Hyperfect
reagent.
HIV infection, provirus transfection and cocultures
Two days prior to coculture, MT4C5 or activated primary CD4
T cells were infected with the indicated virus for 3 h at 37uC in the
presence of 2 mg/mL DEAE Dextran (Sigma-Aldrich). MT4C5
cells expressing NLDEnv and NLF522Y mutants, were obtained
by infection with VSV-G pseudotyped viruses. The levels of living
cells and of infected cells were assessed by cytometry analysis after
HIV Gag staining. To distinguish donor or target cells, one of the
population was stained with CarboxyFluorescein Diacetate
Succinimidyl Ester (CFSE, 2.5 mM; Molecular Probes) for
10 mn at 37uC. Donor and target cells were then mixed at a
ratio of 1:2 or 1:5 (PBMCs, PBMC-pDCs, Gen2.2) or 2:1 (pDCs)
in 96-well plate at a final concentration of 0.75610
6/mL (for
PBMCs, PBMC-pDCs, Gen2.2), and 0.35610
6/mL (for pDCs) in
a final volume of 250 mL. When stated, the indicated inhibitors
were added to target cells 1 h before and maintained during the
coculture.
HeLa cells (2610
4 cells per well, in 48-well plates) were
transfected with the indicated HIV proviral vectors (1 mg) by
lipofection (RotiH-Fect PLUS, Carl Roth GmbH) following
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were added at a concentration of 0.5610
6/mL. The infectivity of
virions released in the supernatant of transfected HeLa cells was
assessed using P4C5 cells [49]. Gen2.2 (10
6 cells/well) were
infected with the indicated doses of viruses, and HIV replication
was assessed by following the appearance of Gag+ cells by flow
cytometry and by measuring Gag-p24 release in supernatants by
ELISA.
Surface and intracellular staining
Cell surface stainings were performed at 4uC for 30 mn using
anti-BDCA2-APC, anti-BDCA4-PE (Miltenyi Biotech), anti-CD4-
PE (SK3, BD-Pharmingen), uncoupled anti-CCR5 (2D7, BD
Pharmingen) and anti CXCR4 (12G5, NIH AIDS Research and
Reference Reagent Program), followed by goat anti-mouse Ig
(H+L)-PE (Southern Biotechnologies). Cells were intracellularly
stained with anti-HIV-Gag (KC57-PE, Beckman-Coulter) and
anti-MxA (a kind gift of Dr. O. Haller). Briefly, cells were fixed for
10 mn with PBS 4 % paraformaldehyde, washed, permeabilized
and stained for 45 min in PBS containing 1 % BSA and 0.05 %
saponin. Isotype-matched mAbs were used as negative controls.
Samples were analyzed by flow cytometry using a FacsCalibur
(Becton Dickinson) or a FacsCanto II (Becton Dickinson) with
FlowJo or FacsDIVA softwares.
Confocal imaging
For conjugates analysis, HIV-infected MT4C5 cells were mixed
with CFSE-labelled Gen2.2 cells at a 1:1 ratio and loaded on
polylysine-coated coverslips (6610
5 cells in 400 ml). After 1 h at
37uC, cells were fixed and stained with an anti-Gag p24 and
analyzed by confocal microscopy as described [76].
Lentiviral transduction
Gen2.2 were transduced using lentiviral vector (LV) particles
containing shRNA targeting TLR7 (NM_016562) Clone ID:
TRCN0000056974 (OpenBiosystem) or control shRNA. The
BVDV-NPro coding lentiviral vector has been described [77].
293T-4X4 cellswere transducedwith aLVexpressingBVDV-Npro.
The LV express also the puroR gene. Two days after
transduction, Gen2.2 or 293T-4X4 cells were selected in the
presence of 1 mg/mL puromycin. Resistant populations grew in a
few days, and were used without further subcloning.
Isolation of RNA and RT-PCR
Total RNA from Gen2.2 and 293T-4X4 cells were extracted
using RNeasy Mini Kit (Qiagen), and cDNA was synthesized
from 1 mg RNA using oligo-dT (Roche) and Superscript reverse
transcriptase (Invitrogen) according to the manufacturers’
instructions. Quantitative real-time PCR was performed as
described [78] using the TaqMan gene expression assays
technology (Applied Biosystems) for TLR7 (Hs00152971_m1),
RIG-I (Hs00204833_m1), and MDA5 (Hs01070329_m1).
GAPDH was used as a housekeeping gene to normalize mRNA
expression. The ratio of gene of interest versus housekeeping gene
was calculated according to the following formula: ratio =2
2dCt
(dCT = mean Ct gene 2 mean Ct housekeeping). The mRNA
relative level was calculated as the ratio between mRNA in
transduced cells and mRNA in shCTRL cells. The reactions were
run on a PTC200 equipped with a Chromo4 detector and
analyses were performed with Opticon Monitor software version
2.03 (MJ Research). All the measures were performed in
duplicate and validated when the difference in threshold cycle
(Ct) between the 2 measures was ,0.3.
IFN detection
IFN secretion was quantified using the reporter cell line HL116,
that carries the luciferase gene under the control of the IFN-
inducible 6-16 promoter (a kind gift from Sandra Pellegrini,
Institut Pasteur, France) [79]. HL116 were grown in DMEM
supplemented with 10% FBS and HAT (H: 20 mg/mL, T: 20 mg/
mL, A: 0.2 mg/mL). 2610
4 HL116 cells, plated 16 h prior the
assay in 96-well plate, were incubated for 7 h with the desired
culture supernatants or standards containing a titration of human
IFNa2a (Immunotools). Cells were then lysed (Luciferase Cell
Culture Lysis, 5X Reagent, Promega) and luciferase activity
measured using the Luciferase Assay Reagent (Promega). Samples
were analyzed using Perkin Elmer Wallac 1420. IFN levels are
expressed as equivalent of IFNa2a concentration, in Unit/mL.
Transient transfection and reporter gene assay
293T, 293T CXCR4 or 293T-4X4 cells were transfected using
FuGENE 6 (Roche Diagnostics) according to the manufacturer’s
instructions. Cells were transiently cotransfected with 100 ng of
IFNb promoter-luciferase (generously provided by Dr. R. Weil
and J. Hiscott), 20 ng of pRSV-b-galactosidase to control DNA
uptake and expression. After 24 h, cells were exposed to SeV or or
cocultured with HIV-infected MT4C5 at a ratio 1:1 for 16 h. Cells
were processed as previously reported [80]. Results are expressed
as relative luciferase units (RLU) normalized with b-galactosidase
activity. For silencing experiments, cell were transfected with
siRNAs and were processed 48 h later as described above.
Data and statistical analysis
Results of experiments are expressed as mean+SD. Compari-
sons between groups were performed using the Kruskal-Wallis test.
Differences with a p-value of less than 0.05 were considered
statistically significant.
Supporting Information
Figure S1 a. Flow cytometry profile of PBMCs, PBMCs
depeleted from pDCs, and enriched pDCs. Cells are stained for
BDCA4 and BDCA2 expression. The % of double positive cells in
the circles are indicated. Results from one donor are representative
of at least 5 independent donors. b. Expression of the IFN-
inducible MXA protein by pDCs. pDCs were either left
unstimulated (alone), exposed to the indicated amounts of cell-
free HIV, to FLU, or coultivated with MT4C5 cells, either non
infected (NI) or infected at two MOIs (high or low). 24h later, cells
were stained for MXA and analyzed by flow cytometry. pDCs and
MT4C5 cells were distinguished according to their SSC-H profile
(X-axis). Results from one donor are representative of 3 inde-
pendent donors.
Found at: doi:10.1371/journal.ppat.1001284.s001 (0.67 MB TIF)
Figure S2 HIV replication and IFN production in
PBMCs. PBMCs were activated with PHA and cultivated with
IL-2, and 3 days later were exposed to HIV particles, NL4-3
strain, (10 ng/0.1 ml Gag p24/106 cells). Viral replication was
assessed by following the appearance of Gag+ cells (left panel).
IFN production was measured in supernatants (right panel).
Data are representative of 3 independent experiments.
Found at: doi:10.1371/journal.ppat.1001284.s002 (0.18 MB TIF)
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